{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T02:01:56Z","timestamp":1774922516939,"version":"3.50.1"},"reference-count":49,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Instituto de Salud Carlos III","award":["PI18\/01600"],"award-info":[{"award-number":["PI18\/01600"]}]},{"name":"Instituto de Salud Carlos III","award":["PI19\/01384"],"award-info":[{"award-number":["PI19\/01384"]}]},{"name":"Instituto de Salud Carlos III","award":["PI21\/01508"],"award-info":[{"award-number":["PI21\/01508"]}]},{"name":"Instituto de Salud Carlos III","award":["PI22\/00877"],"award-info":[{"award-number":["PI22\/00877"]}]},{"name":"Instituto de Salud Carlos III","award":["PROYE20047GUTI"],"award-info":[{"award-number":["PROYE20047GUTI"]}]},{"name":"Instituto de Salud Carlos III","award":["FRA16\/003"],"award-info":[{"award-number":["FRA16\/003"]}]},{"name":"Instituto de Salud Carlos III","award":["FPU22\/04397"],"award-info":[{"award-number":["FPU22\/04397"]}]},{"name":"Instituto de Salud Carlos III","award":["INVES18043PA\u00cdN"],"award-info":[{"award-number":["INVES18043PA\u00cdN"]}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["PI18\/01600"],"award-info":[{"award-number":["PI18\/01600"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["PI19\/01384"],"award-info":[{"award-number":["PI19\/01384"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["PI21\/01508"],"award-info":[{"award-number":["PI21\/01508"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["PI22\/00877"],"award-info":[{"award-number":["PI22\/00877"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["PROYE20047GUTI"],"award-info":[{"award-number":["PROYE20047GUTI"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["FRA16\/003"],"award-info":[{"award-number":["FRA16\/003"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["FPU22\/04397"],"award-info":[{"award-number":["FPU22\/04397"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["INVES18043PA\u00cdN"],"award-info":[{"award-number":["INVES18043PA\u00cdN"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ram\u00f3n Areces","doi-asserted-by":"publisher","award":["PI18\/01600"],"award-info":[{"award-number":["PI18\/01600"]}],"id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ram\u00f3n Areces","doi-asserted-by":"publisher","award":["PI19\/01384"],"award-info":[{"award-number":["PI19\/01384"]}],"id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ram\u00f3n Areces","doi-asserted-by":"publisher","award":["PI21\/01508"],"award-info":[{"award-number":["PI21\/01508"]}],"id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ram\u00f3n Areces","doi-asserted-by":"publisher","award":["PI22\/00877"],"award-info":[{"award-number":["PI22\/00877"]}],"id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ram\u00f3n Areces","doi-asserted-by":"publisher","award":["PROYE20047GUTI"],"award-info":[{"award-number":["PROYE20047GUTI"]}],"id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ram\u00f3n Areces","doi-asserted-by":"publisher","award":["FRA16\/003"],"award-info":[{"award-number":["FRA16\/003"]}],"id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ram\u00f3n Areces","doi-asserted-by":"publisher","award":["FPU22\/04397"],"award-info":[{"award-number":["FPU22\/04397"]}],"id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ram\u00f3n Areces","doi-asserted-by":"publisher","award":["INVES18043PA\u00cdN"],"award-info":[{"award-number":["INVES18043PA\u00cdN"]}],"id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mundipharma Research Limited","award":["PI18\/01600"],"award-info":[{"award-number":["PI18\/01600"]}]},{"name":"Mundipharma Research Limited","award":["PI19\/01384"],"award-info":[{"award-number":["PI19\/01384"]}]},{"name":"Mundipharma Research Limited","award":["PI21\/01508"],"award-info":[{"award-number":["PI21\/01508"]}]},{"name":"Mundipharma Research Limited","award":["PI22\/00877"],"award-info":[{"award-number":["PI22\/00877"]}]},{"name":"Mundipharma Research Limited","award":["PROYE20047GUTI"],"award-info":[{"award-number":["PROYE20047GUTI"]}]},{"name":"Mundipharma Research Limited","award":["FRA16\/003"],"award-info":[{"award-number":["FRA16\/003"]}]},{"name":"Mundipharma Research Limited","award":["FPU22\/04397"],"award-info":[{"award-number":["FPU22\/04397"]}]},{"name":"Mundipharma Research Limited","award":["INVES18043PA\u00cdN"],"award-info":[{"award-number":["INVES18043PA\u00cdN"]}]},{"name":"Purdue Pharma","award":["PI18\/01600"],"award-info":[{"award-number":["PI18\/01600"]}]},{"name":"Purdue Pharma","award":["PI19\/01384"],"award-info":[{"award-number":["PI19\/01384"]}]},{"name":"Purdue Pharma","award":["PI21\/01508"],"award-info":[{"award-number":["PI21\/01508"]}]},{"name":"Purdue Pharma","award":["PI22\/00877"],"award-info":[{"award-number":["PI22\/00877"]}]},{"name":"Purdue Pharma","award":["PROYE20047GUTI"],"award-info":[{"award-number":["PROYE20047GUTI"]}]},{"name":"Purdue Pharma","award":["FRA16\/003"],"award-info":[{"award-number":["FRA16\/003"]}]},{"name":"Purdue Pharma","award":["FPU22\/04397"],"award-info":[{"award-number":["FPU22\/04397"]}]},{"name":"Purdue Pharma","award":["INVES18043PA\u00cdN"],"award-info":[{"award-number":["INVES18043PA\u00cdN"]}]},{"name":"Consejer\u00eda de Educaci\u00f3n (Junta de Castilla y Le\u00f3n)","award":["PI18\/01600"],"award-info":[{"award-number":["PI18\/01600"]}]},{"name":"Consejer\u00eda de Educaci\u00f3n (Junta de Castilla y Le\u00f3n)","award":["PI19\/01384"],"award-info":[{"award-number":["PI19\/01384"]}]},{"name":"Consejer\u00eda de Educaci\u00f3n (Junta de Castilla y Le\u00f3n)","award":["PI21\/01508"],"award-info":[{"award-number":["PI21\/01508"]}]},{"name":"Consejer\u00eda de Educaci\u00f3n (Junta de Castilla y Le\u00f3n)","award":["PI22\/00877"],"award-info":[{"award-number":["PI22\/00877"]}]},{"name":"Consejer\u00eda de Educaci\u00f3n (Junta de Castilla y Le\u00f3n)","award":["PROYE20047GUTI"],"award-info":[{"award-number":["PROYE20047GUTI"]}]},{"name":"Consejer\u00eda de Educaci\u00f3n (Junta de Castilla y Le\u00f3n)","award":["FRA16\/003"],"award-info":[{"award-number":["FRA16\/003"]}]},{"name":"Consejer\u00eda de Educaci\u00f3n (Junta de Castilla y Le\u00f3n)","award":["FPU22\/04397"],"award-info":[{"award-number":["FPU22\/04397"]}]},{"name":"Consejer\u00eda de Educaci\u00f3n (Junta de Castilla y Le\u00f3n)","award":["INVES18043PA\u00cdN"],"award-info":[{"award-number":["INVES18043PA\u00cdN"]}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PI18\/01600"],"award-info":[{"award-number":["PI18\/01600"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PI19\/01384"],"award-info":[{"award-number":["PI19\/01384"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PI21\/01508"],"award-info":[{"award-number":["PI21\/01508"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PI22\/00877"],"award-info":[{"award-number":["PI22\/00877"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PROYE20047GUTI"],"award-info":[{"award-number":["PROYE20047GUTI"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["FRA16\/003"],"award-info":[{"award-number":["FRA16\/003"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["FPU22\/04397"],"award-info":[{"award-number":["FPU22\/04397"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["INVES18043PA\u00cdN"],"award-info":[{"award-number":["INVES18043PA\u00cdN"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["PI18\/01600"],"award-info":[{"award-number":["PI18\/01600"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["PI19\/01384"],"award-info":[{"award-number":["PI19\/01384"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["PI21\/01508"],"award-info":[{"award-number":["PI21\/01508"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["PI22\/00877"],"award-info":[{"award-number":["PI22\/00877"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["PROYE20047GUTI"],"award-info":[{"award-number":["PROYE20047GUTI"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["FRA16\/003"],"award-info":[{"award-number":["FRA16\/003"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["FPU22\/04397"],"award-info":[{"award-number":["FPU22\/04397"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["INVES18043PA\u00cdN"],"award-info":[{"award-number":["INVES18043PA\u00cdN"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Multiple myeloma is a malignancy characterized by the accumulation of malignant plasma cells in bone marrow and the production of monoclonal immunoglobulin. A hallmark of cancer is the evasion of immune surveillance. Histone deacetylase inhibitors have been shown to promote the expression of silenced molecules and hold potential to increase the anti-MM efficacy of immunotherapy. The aim of the present work was to assess the potential effect of tinostamustine (EDO-S101), a first-in-class alkylating deacetylase inhibitor, in combination with daratumumab, an anti-CD38 monoclonal antibody (mAb), through different preclinical studies. Tinostamustine increases CD38 expression in myeloma cell lines, an effect that occurs in parallel with an increment in CD38 histone H3 acetylation levels. Also, the expression of MICA and MICB, ligands for the NK cell activating receptor NKG2D, augments after tinostamustine treatment in myeloma cell lines and primary myeloma cells. Pretreatment of myeloma cell lines with tinostamustine increased the sensitivity of these cells to daratumumab through its different cytotoxic mechanisms, and the combination of these two drugs showed a higher anti-myeloma effect than individual treatments in ex vivo cultures of myeloma patients\u2019 samples. In vivo data confirmed that tinostamustine pretreatment followed by daratumumab administration significantly delayed tumor growth and improved the survival of mice compared to individual treatments. In summary, our results suggest that tinostamustine could be a potential candidate to improve the efficacy of anti-CD38 mAbs.<\/jats:p>","DOI":"10.3390\/ijms25094718","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T05:13:41Z","timestamp":1714108421000},"page":"4718","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0802-9767","authenticated-orcid":false,"given":"Andrea","family":"D\u00edaz-Tejedor","sequence":"first","affiliation":[{"name":"Centro de Investigaci\u00f3n del C\u00e1ncer-Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer (CIC-IBMCC), Universidad de Salamanca, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), 37007 Salamanca, Spain"},{"name":"Servicio de Hematolog\u00eda, Complejo Asistencial Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Rodr\u00edguez-Ubreva","sequence":"additional","affiliation":[{"name":"Epigenetics and Immune Disease Group, Josep Carreras Research Institute (IJC), 08916 Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Ciudad","sequence":"additional","affiliation":[{"name":"Epigenetics and Immune Disease Group, Josep Carreras Research Institute (IJC), 08916 Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8388-845X","authenticated-orcid":false,"given":"Mauro","family":"Lorenzo-Mohamed","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n del C\u00e1ncer-Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer (CIC-IBMCC), Universidad de Salamanca, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), 37007 Salamanca, Spain"},{"name":"Servicio de Hematolog\u00eda, Complejo Asistencial Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Gonz\u00e1lez-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n del C\u00e1ncer-Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer (CIC-IBMCC), Universidad de Salamanca, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), 37007 Salamanca, Spain"},{"name":"Servicio de Hematolog\u00eda, Complejo Asistencial Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e1rbara","family":"Castellanos","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n del C\u00e1ncer-Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer (CIC-IBMCC), Universidad de Salamanca, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), 37007 Salamanca, Spain"},{"name":"Servicio de Hematolog\u00eda, Complejo Asistencial Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Sotolongo-Ravelo","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n del C\u00e1ncer-Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer (CIC-IBMCC), Universidad de Salamanca, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), 37007 Salamanca, Spain"},{"name":"Servicio de Hematolog\u00eda, Complejo Asistencial Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2391-5935","authenticated-orcid":false,"given":"Laura","family":"San-Segundo","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n del C\u00e1ncer-Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer (CIC-IBMCC), Universidad de Salamanca, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), 37007 Salamanca, Spain"},{"name":"Servicio de Hematolog\u00eda, Complejo Asistencial Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4577-8599","authenticated-orcid":false,"given":"Luis A.","family":"Corchete","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n del C\u00e1ncer-Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer (CIC-IBMCC), Universidad de Salamanca, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), 37007 Salamanca, Spain"},{"name":"Servicio de Hematolog\u00eda, Complejo Asistencial Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica En Red de C\u00e1ncer (CIBERONC, CB16\/12\/00233), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Gonz\u00e1lez-M\u00e9ndez","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n del C\u00e1ncer-Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer (CIC-IBMCC), Universidad de Salamanca, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), 37007 Salamanca, Spain"},{"name":"Servicio de Hematolog\u00eda, Complejo Asistencial Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Mart\u00edn-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n del C\u00e1ncer-Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer (CIC-IBMCC), Universidad de Salamanca, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), 37007 Salamanca, Spain"},{"name":"Servicio de Hematolog\u00eda, Complejo Asistencial Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n del C\u00e1ncer-Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer (CIC-IBMCC), Universidad de Salamanca, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), 37007 Salamanca, Spain"},{"name":"Servicio de Hematolog\u00eda, Complejo Asistencial Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica En Red de C\u00e1ncer (CIBERONC, CB16\/12\/00233), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain"},{"name":"Departamento de Medicina, Universidad de Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5765-0085","authenticated-orcid":false,"given":"Enrique M.","family":"Ocio","sequence":"additional","affiliation":[{"name":"Hospital Universitario Marqu\u00e9s de Valdecilla (IDIVAL), Universidad de Cantabria, 39008 Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2194-2841","authenticated-orcid":false,"given":"Mercedes","family":"Garayoa","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n del C\u00e1ncer-Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer (CIC-IBMCC), Universidad de Salamanca, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), 37007 Salamanca, Spain"},{"name":"Servicio de Hematolog\u00eda, Complejo Asistencial Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-3572","authenticated-orcid":false,"given":"Teresa","family":"Pa\u00edno","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n del C\u00e1ncer-Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer (CIC-IBMCC), Universidad de Salamanca, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), 37007 Salamanca, Spain"},{"name":"Servicio de Hematolog\u00eda, Complejo Asistencial Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica En Red de C\u00e1ncer (CIBERONC, CB16\/12\/00233), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain"},{"name":"Departamento de Fisiolog\u00eda y Farmacolog\u00eda, Universidad de Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2119\/molmed.2013.00009","article-title":"Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule","volume":"19","author":"Chillemi","year":"2013","journal-title":"Mol. Med."},{"key":"ref_3","first-page":"70","article-title":"Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma","volume":"9","author":"Raedler","year":"2016","journal-title":"Am. Health Drug Benefits"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, Dexamethasone, and Daratumumab versus Carfilzomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (CANDOR): Results from a Randomised, Multicentre, Open-Label, Phase 3 Study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus Pomalidomide and Dexamethasone versus Pomalidomide and Dexamethasone Alone in Previously Treated Multiple Myeloma (APOLLO): An Open-Label, Randomised, Phase 3 Trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, Thalidomide, and Dexamethasone with or without Daratumumab before and after Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open-Label, Phase 3 Study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of CD38 Expression on Multiple Myeloma Cells by All-Trans Retinoic Acid Improves the Efficacy of Daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance","volume":"9","author":"Usmani","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors","volume":"186","author":"Tai","year":"2011","journal-title":"J. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-Mediated Phagocytosis Contributes to the Anti-Tumor Activity of the Therapeutic Antibody Daratumumab in Lymphoma and Multiple Myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fc\u03b3 Receptor-Mediated Cross-Linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"D\u00edaz-Tejedor, A., Lorenzo-Mohamed, M., Puig, N., Garc\u00eda-Sanz, R., Mateos, M.-V., Garayoa, M., and Pa\u00edno, T. (2021). Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression. Cancers, 13.","DOI":"10.3390\/cancers13061353"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 Expression and Complement Inhibitors Affect Response and Resistance to Daratumumab Therapy in Myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1182\/blood-2017-03-770776","article-title":"Panobinostat Induces CD38 Upregulation and Augments the Antimyeloma Efficacy of Daratumumab","volume":"129","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s41375-019-0587-5","article-title":"DNA Methyltransferase Inhibitors Upregulate CD38 Protein Expression and Enhance Daratumumab Efficacy in Multiple Myeloma","volume":"34","author":"Choudhry","year":"2020","journal-title":"Leukemia"},{"key":"ref_20","first-page":"201","article-title":"Upregulation of CD38 Expression on Multiple Myeloma Cells by Novel HDAC6 Inhibitors Is a Class Effect and Augments the Efficacy of Daratumumab","volume":"35","author":"Doose","year":"2020","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1158\/0008-5472.CAN-04-4252","article-title":"Natural Killer Cell-Mediated Lysis of Hepatoma Cells via Specific Induction of NKG2D Ligands by the Histone Deacetylase Inhibitor Sodium Valproate","volume":"65","author":"Armeanu","year":"2005","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/CMR.0b013e328364c0ed","article-title":"The Antimelanoma Activity of the Histone Deacetylase Inhibitor Panobinostat (LBH589) Is Mediated by Direct Tumor Cytotoxicity and Increased Tumor Immunogenicity","volume":"23","author":"Woods","year":"2013","journal-title":"Melanoma Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13046-021-01909-7","article-title":"Small-Molecule HDAC and Akt Inhibitors Suppress Tumor Growth and Enhance Immunotherapy in Multiple Myeloma","volume":"40","author":"Hirano","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1593\/neo.121236","article-title":"Valproic Acid Upregulates NKG2D Ligand Expression through an ERK-Dependent Mechanism and Potentially Enhances NK Cell-Mediated Lysis of Myeloma","volume":"14","author":"Wu","year":"2012","journal-title":"Neoplasia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.semcancer.2019.12.019","article-title":"Combining Epigenetic and Immune Therapy to Overcome Cancer Resistance","volume":"65","author":"Gomez","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/blood-2008-08-173914","article-title":"ATM-ATR\u2013Dependent up-Regulation of DNAM-1 and NKG2D Ligands on Multiple Myeloma Cells by Therapeutic Agents Results in Enhanced NK-Cell Susceptibility and Is Associated with a Senescent Phenotype","volume":"113","author":"Soriani","year":"2009","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.molimm.2004.07.028","article-title":"PVR (CD155) and Nectin-2 (CD112) as Ligands of the Human DNAM-1 (CD226) Activating Receptor: Involvement in Tumor Cell Lysis","volume":"42","author":"Pende","year":"2005","journal-title":"Mol. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/hon.2326","article-title":"Increase of CIK Cell Efficacy by Upregulating Cell Surface MICA and Inhibition of NKG2D Ligand Shedding in Multiple Myeloma: Increase of CIK Cell Efficacy Against","volume":"35","author":"Nwangwu","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.18632\/oncotarget.26726","article-title":"PD-L1 Upregulation in Myeloma Cells by Panobinostat in Combination with Interferon-\u03b3","volume":"10","author":"Iwasa","year":"2019","journal-title":"Oncotarget"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2174\/1871520615666150518092027","article-title":"The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101","volume":"16","author":"Mehrling","year":"2016","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13045-017-0495-y","article-title":"Preclinical Anti-Myeloma Activity of EDO-S101, a New Bendamustine-Derived Molecule with Added HDACi Activity, through Potent DNA Damage Induction and Impairment of DNA Repair","volume":"10","author":"Herrero","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1038\/s41375-020-0772-6","article-title":"Reinstated P53 Response and High Anti-T-Cell Leukemia Activity by the Novel Alkylating Deacetylase Inhibitor Tinostamustine","volume":"34","author":"Varghese","year":"2020","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12032-019-1302-0","article-title":"A Novel Alkylating Deacetylase Inhibitor Molecule EDO-S101 in Combination with Cytarabine Synergistically Enhances Apoptosis of Acute Myeloid Leukemia Cells","volume":"36","author":"Jin","year":"2019","journal-title":"Med. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13045-018-0576-6","article-title":"The First-in-Class Alkylating Deacetylase Inhibitor Molecule Tinostamustine Shows Antitumor Effects and Is Synergistic with Radiotherapy in Preclinical Models of Glioblastoma","volume":"11","author":"Festuccia","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"28155","DOI":"10.18632\/oncotarget.25588","article-title":"Combined Alkylation and Histone Deacetylase Inhibition with EDO-S101 Has Significant Therapeutic Activity against Brain Tumors in Preclinical Models","volume":"9","author":"Qiu","year":"2018","journal-title":"Oncotarget"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1002\/cncr.32178","article-title":"Clinical Efficacy of Daratumumab, Pomalidomide, and Dexamethasone in Patients with Relapsed or Refractory Myeloma: Utility of Re-Treatment with Daratumumab among Refractory Patients","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1182\/blood-2018-05-850727","article-title":"IMiDs Prime Myeloma Cells for Daratumumab-Mediated Cytotoxicity through Loss of Ikaros and Aiolos","volume":"132","author":"Fedele","year":"2018","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1139\/o05-041","article-title":"Role of Histone Acetylation in the Control of Gene Expression","volume":"83","author":"Verdone","year":"2005","journal-title":"Biochem. Cell Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"255","DOI":"10.18632\/oncotarget.6353","article-title":"Taxanes Enhance Trastuzumab-Mediated ADCC on Tumor Cells through NKG2D-Mediated NK Cell Recognition","volume":"7","author":"Sfondrini","year":"2016","journal-title":"Oncotarget"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1158\/2326-6066.CIR-19-0483","article-title":"Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells","volume":"8","author":"Kumar","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"11136","DOI":"10.1158\/0008-5472.CAN-05-0599","article-title":"Cancer Cells Become Susceptible to Natural Killer Cell Killing after Exposure to Histone Deacetylase Inhibitors Due to Glycogen Synthase Kinase-3-Dependent Expression of MHC Class I-Related Chain A and B","volume":"65","author":"Skov","year":"2005","journal-title":"Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41409-019-0601-6","article-title":"Adoptive Cell Therapy Using Engineered Natural Killer Cells","volume":"54","author":"Rezvani","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Shiozawa, M., Chang, C.-H., Huang, Y.-C., Chen, Y.-C., Chi, M.-S., Hao, H.-C., Chang, Y.-C., Takeda, S., Chi, K.-H., and Wang, Y.-S. (2018). Pharmacologically Upregulated Carcinoembryonic Antigen-Expression Enhances the Cytolytic Activity of Genetically-Modified Chimeric Antigen Receptor NK-92MI against Colorectal Cancer Cells. BMC Immunol., 19.","DOI":"10.1186\/s12865-018-0262-z"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Pa\u00edno, T., Gonz\u00e1lez-M\u00e9ndez, L., San-Segundo, L., Corchete, L.A., Hern\u00e1ndez-Garc\u00eda, S., D\u00edaz-Tejedor, A., Algar\u00edn, E.M., Mogoll\u00f3n, P., Mart\u00edn-S\u00e1nchez, M., and Guti\u00e9rrez, N.C. (2020). Protein Translation Inhibition Is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12102743"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/nar\/gkab1182","article-title":"Coordinated Glucocorticoid Receptor and MAFB Action Induces Tolerogenesis and Epigenome Remodeling in Dendritic Cells","volume":"50","author":"Ciudad","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1182\/blood-2008-09-177774","article-title":"Zalypsis: A Novel Marine-Derived Compound with Potent Antimyeloma Activity That Reveals High Sensitivity of Malignant Plasma Cells to DNA Double-Strand Breaks","volume":"113","author":"Ocio","year":"2009","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Verkleij, C.P.M., Jhatakia, A., Broekmans, M.E.C., Frerichs, K.A., Zweegman, S., Mutis, T., Bezman, N.A., and van de Donk, N.W.C.J. (2020). Preclinical Rationale for Targeting the PD-1\/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies. Cancers, 12.","DOI":"10.3390\/cancers12123713"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.4049\/jimmunol.134.6.3798","article-title":"Natural Killer (NK) Cells Are Present in Mice with Severe Combined Immunodeficiency (Scid)","volume":"134","author":"Dorshkind","year":"1985","journal-title":"J. Immunol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4718\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:33:43Z","timestamp":1760106823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":49,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["ijms25094718"],"URL":"https:\/\/doi.org\/10.3390\/ijms25094718","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,26]]}}}